To verify this hypothesis, it is necessary to evaluate the expression and function of LIS1 in CD133+ CSC isolated from the most frequent solid cancers: breast cancer, lung cancer, colorectal cancer and melanoma. This evidence concerns the gene PROM1 and breast carcinoma.